This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

48/100

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Biomarkers

Topic: Brain proteins, microglia and lab models

Background and objectives Elevations in circulating glial fibrillary acidic protein (GFAP), a putative marker of reactive astrocytosis, have been found to associate with cognitive decline and dementia status. Further validation in diverse cohorts and evaluation of potential health disparities are necessary for broader generalization. The goal of this study was to examine the associations between demographics, cardiovascular risk factors, and APOE ε4 status with serum GFAP levels among Mexican American and non-Hispanic White older adults across the continuum from cognitively unimpaired to Alzheimer disease dementia. Methods Serum GFAP levels were assayed using a Simoa HD-1 analyzer in older adults enrolled in the observational Texas Alzheimer Research and Care Consortium. Associations between demographic and clinical characteristics with serum GFAP levels were evaluated using linear regression. The diagnostic accuracy of serum GFAP was further examined using area under the receiver operating characteristic curves (AUROC) in univariate and adjusted models, and optimal cut points were derived using the maximum Kolmogorov-Smirnov metric. All models were also stratified by ethnicity and disease stage. Results A total of 1,156 Mexican American and 587 non-Hispanic White participants were included (mean age = 68 years, standard deviation = 10; 65% female). Older age (β = 0.562 (95% CI 0.515-0.609), p p p p p p Discussion The study results highlight the importance of understanding the role of broader demographic and clinical factors on circulating GFAP levels within diverse cohorts to enhance precision across clinical, research, and community settings.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gonzales, M. M., Vela, G., Philip, V., Trevino, H., LaRoche, A., Wang, C. P., et al. (2023). Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort. Neurology. https://doi.org/10.1212/wnl.0000000000207706

Vancouver

Gonzales MM, Vela G, Philip V, Trevino H, LaRoche A, Wang CP, et al. Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort. Neurology. 2023. doi:10.1212/wnl.0000000000207706. PMID: 37813589.

BibTeX

@article{gonzales2023-37813589,
  author  = {Gonzales, M. M. and Vela, G. and Philip, V. and Trevino, H. and LaRoche, A. and Wang, C. P. and Parent, D. M. and Kautz, T. and others},
  title   = {{Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207706},
  pmid    = {37813589},
  url     = {https://doi.org/10.1212/wnl.0000000000207706}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Results A total of 1,156 Mexican American and 587 non-Hispanic White participants were included (mean age = 68 years, standard deviation = 10; 65% female).
Older age (β = 0.562 (95% CI 0.515-0.609), p p p p p p Discussion The study results highlight the importance of understanding the role of broader demographic and clinical factors on circulating GFAP levels within diverse cohorts to enhance precision across clinical, research, and community settings.

Why it matters

In 1,156 Mexican American and 587 non-Hispanic White older adults, serum GFAP levels were associated with demographic and clinical factors, and the study examined its diagnostic accuracy. This is about understanding a biomarker across diverse groups, not about treating, curing or preventing Alzheimer's disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Participants1,156
Evidence strengthLow

How this study scored 48/100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Neurology)
Journal's citation record	4 / 4	Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	3 / 5	2023 — within 6 year(s) of the newest study here
Sample size	3 / 4	1,156 participants
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 13 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.6 citations a year over 5 year(s) since 2023
Impact for its field and year	2 / 6	Cited 2.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	1 / 4	Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Sudha S. Seshadri: h-index 148 (OpenAlex, whole career)
Institution's track record	1 / 3	Boston University: institution h-index 1,456 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 37813589)
Free to read	0 / 2	Behind a paywall — scores zero
Total	48 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Biomarkers

Also in Biomarkers

147 studies in the library are filed under Biomarkers with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Biomarkers hub.

Similar studies

More on Biomarkers

See all studies in Biomarkers →